 Shares of Chimerix Inc. CMRX, 3.41 shot up 14.4 in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent BioSolutions Inc. for up to 337.5 million plus royalties. Emergent BioSolutions shares were still inactive ahead of the open. 